Clinical Trials Browser

Terminated × cabozantinib × Genitourinary × Clear all

NCT04631744 2026-05-01

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 2 Terminated

4 enrolled 11 charts

Prostatic Neoplasms

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT06716853 2026-02-09

TEM-GU

Phase 1/2 Terminated

Carcinoma, Renal Cell

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT06377722 2024-04-26

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Phase 2 Terminated

Carcinoma, Renal Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1/2 Terminated

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03964337 2022-06-29

SPARC

Phase 2 Terminated

3 enrolled 5 charts

Prostatic Neoplasms

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04066595 2021-08-30

CabUC

Phase 2 Terminated

Carcinoma, Transitional Cell

NCT01703065 2018-12-04

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Phase 2 Terminated

9 enrolled 10 charts

Prostatic Neoplasms

NCT01522443 2018-05-23

COMET-2

Phase 3 Terminated

119 enrolled 21 charts

Pain, Prostatic Neoplasms